0001104659-15-049012.txt : 20150630
0001104659-15-049012.hdr.sgml : 20150630
20150630184533
ACCESSION NUMBER: 0001104659-15-049012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150630
FILED AS OF DATE: 20150630
DATE AS OF CHANGE: 20150630
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CATABASIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001454789
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 1400E, SUITE B14202
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-349-1971
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BLDG. 1400E, SUITE B14202
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MedImmune Ventures, Inc.
CENTRAL INDEX KEY: 0001291884
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37467
FILM NUMBER: 15962715
BUSINESS ADDRESS:
STREET 1: ONE MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 301-398-0000
MAIL ADDRESS:
STREET 1: ONE MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
a4.xml
4
X0306
4
2015-06-30
0
0001454789
CATABASIS PHARMACEUTICALS INC
CATB
0001291884
MedImmune Ventures, Inc.
ONE MEDIMMUNE WAY
GAITHERSBURG
MD
20878
0
0
1
0
Common Stock
2015-06-30
4
C
0
1079115
A
1079115
D
Common Stock
2015-06-30
4
C
0
330098
A
1409213
D
Common Stock
2015-06-30
4
P
0
223439
12
A
1632652
D
Series A Preferred Stock
2015-06-30
4
C
0
13866666
0
D
Common Stock
1079115
0
D
Series B Preferred Stock
2015-06-30
4
C
0
4241780
0
D
Common Stock
330098
0
D
The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by MedImmune Ventures, Inc. Ron Laufer is the Senior Managing Partner of MedImmune Ventures, Inc., and as a result, Dr. Laufer may be deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures, Inc. Dr. Laufer disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
/s/ Andrea Matthews, attorney-in-fact for MedImmune Ventures, Inc.
2015-06-30